Keros Therapeutics Welcomes Dr. Yung H. Chyung As Chief Medical Officer To Drive Innovation

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and trade of innovative therapies for disorders related to dysfunctional signalling of the transforming growth factor-beta (TGF-ß) protein family, has announced the appointment of Dr. Yung H. Chyung as Chief Medical Officer, effective from November 1, 2024.

Chair and Chief Executive Officer Jasbir Seehra, PhD, said, “We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs.”

“We believe Yung’s experience and leadership will be invaluable at this critical point as we prepare to initiate a Phase 3 clinical trial evaluating elritercept (KER-050) in patients with lower-risk myelodysplastic syndromes and for important data readouts for cibotercept (KER-012) and KER-065 expected in 2025,” stated the President and Chief Operating Officer Christopher Rovaldi.

Dr Yung H. Chyung mentioned, “I am delighted to be joining Keros at this exciting time for the company, as it prepares for its first registrational clinical trial and upcoming topline data readout for the TROPOS trial, the ongoing Phase 2 clinical trial of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension. I look forward to joining Keros’ talented and dedicated team to bring our differentiated product candidates to patients with limited treatment options.”

Dr. Chyung previously held the position of Executive Vice President and Chief Medical Officer at Tourmaline Bio, Inc. from August 2022 to October 2024. He also served as Chief Medical Officer at Scholar Rock Holding Corporation from February 2016 to June 2022. He has held various roles at Dyax Corp, lately as Vice President of Medical Research, and has experience at Genzyme Corporation. Dr. Chyung holds an A.B. in Biochemical Sciences from Harvard College and an M.D. from Harvard Medical School. He completed his residency in internal medicine and a fellowship in allergy and immunology at Massachusetts General Hospital.